The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib (GIDEON): Sorafenib dosing and safety in U.S. patients.
Anthony B. El-Khoueiry
Consultant or Advisory Role - Bayer/Onyx
Honoraria - Bayer/Onyx
Research Funding - Bayer/Onyx; Bristol-Myers Squibb
Bilal Piperdi
Honoraria - Bayer/Onyx
Alec Goldenberg
No relevant relationships to disclose
Allen Lee Cohn
No relevant relationships to disclose
Jeff H. Geschwind
Consultant or Advisory Role - Bayer; Biocompatibles International; Guerbet; Nordion
Research Funding - Bayer; Biocompatibles International; CeloNova; ContextVision; Genentech; Nordion; Phillips Medical; RSNA
Jorge A. Marrero
Consultant or Advisory Role - Bayer/Onyx; Bristol-Myers Squibb
Research Funding - Bayer/Onyx; Bristol-Myers Squibb
Arun Sanyal
Employment or Leadership Position - AASLD (U)
Consultant or Advisory Role - Onyx (U)
Research Funding - Bayer/Onyx
Alan Paul Venook
Research Funding - Bayer/Onyx